In 298 analysed adults with newly diagnosed resectable glioblastoma, adding 30 Gy intraoperative radiotherapy to standard care did not improve median progression-free survival (11·0 vs 11·4 months; HR 1·1, p=0·47); serious adverse events were more frequent (65% vs 53%).
RCTn = 314
Giordano et al. Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial